BlackRock Inc. Takes Position in Neogen Corporation $NEOG

BlackRock Inc. acquired a new stake in shares of Neogen Corporation (NASDAQ:NEOG) in the second quarter, HoldingsChannel reports. The institutional investor acquired 33,431,015 shares of the company’s stock, valued at approximately $300,545,000. BlackRock Inc. owned about 0.15% of Neogen at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. UMB Bank n.a. raised its stake in Neogen by 238.2% during the 4th quarter. UMB Bank n.a. now owns 6,422 shares of the company’s stock worth $45,000 after acquiring an additional 4,523 shares during the period. Hantz Financial Services Inc. boosted its position in shares of Neogen by 816.9% in the fourth quarter. Hantz Financial Services Inc. now owns 7,592 shares of the company’s stock worth $53,000 after purchasing an additional 6,764 shares during the period. Cresset Asset Management LLC bought a new position in shares of Neogen in the second quarter worth approximately $53,000. Evergreen Capital Management LLC purchased a new stake in shares of Neogen in the second quarter worth $56,000. Finally, Northwestern Mutual Wealth Management Co. raised its position in shares of Neogen by 3,158.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 8,309 shares of the company’s stock valued at $58,000 after purchasing an additional 8,054 shares during the period. 96.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Neogen from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Piper Sandler upgraded Neogen from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $13.00 to $14.00 in a research note on Wednesday. Finally, Weiss Ratings raised Neogen from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 7th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $12.00.

Neogen News Summary

Here are the key news stories impacting Neogen this week:

• Positive Sentiment: Piper Sandler upgraded Neogen on new management. The brokerage’s improved view suggests investors may expect management changes to improve execution, profitability, or growth. Neogen upgraded at Piper Sandler on new management
• Positive Sentiment: Zacks Research raised several future EPS forecasts. Estimates increased for the second and third quarters of fiscal 2027, the fourth quarter of fiscal 2027, and the third and fourth quarters of fiscal 2028. The full-year fiscal 2028 forecast also rose to $0.29 per share from $0.28, indicating modestly better expected earnings momentum. The current-year consensus remains $0.25 per share.
• Positive Sentiment: Neogen is receiving attention from value-oriented investors. A Zacks comparison of Neogen and Perrigo highlights investor interest in the medical-products sector and could increase visibility for NEOG among investors seeking a relatively attractive valuation. PRGO or NEOG: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Analysts’ price target is near the recent trading level. The reported consensus target of $11.67 suggests limited near-term upside based on that estimate, although targets can change following the Piper Sandler upgrade. Analysts Set Neogen Corporation PT at $11.67
• Neutral Sentiment: Short-interest data provides no meaningful signal. The report lists zero shares sold short and a zero-day short ratio, figures that appear anomalous and do not indicate either significant short-covering potential or notable bearish positioning.
• Negative Sentiment: Not all forecasts improved. Zacks lowered its fiscal first-quarter 2028 EPS estimate to $0.05 from $0.06, signaling that the earnings outlook remains uneven despite the broader upward revisions.

Neogen Trading Up 0.5%

Neogen stock opened at $11.70 on Thursday. Neogen Corporation has a 1 year low of $4.90 and a 1 year high of $12.85. The firm’s 50 day moving average price is $10.37 and its 200-day moving average price is $9.85. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.82 and a quick ratio of 2.91. The stock has a market cap of $2.55 billion, a P/E ratio of -390.00, a PEG ratio of 4.59 and a beta of 1.77.

Neogen (NASDAQ:NEOG) last issued its earnings results on Thursday, July 30th. The company reported $0.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.03. The firm had revenue of $225.30 million during the quarter, compared to analyst estimates of $212.35 million. Neogen had a negative net margin of 0.91% and a positive return on equity of 2.78%. Neogen’s revenue for the quarter was down .1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($2.82) earnings per share. On average, equities analysts predict that Neogen Corporation will post 0.25 earnings per share for the current fiscal year.

Neogen Profile

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen’s product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.